AtriCure Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
AtriCure wird ein jährliches Gewinn- und Umsatzwachstum von 24% bzw. 12.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 27.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -4% betragen.
Wichtige Informationen
24.0%
Wachstumsrate der Gewinne
27.3%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 12.8% |
| Zukünftige Eigenkapitalrendite | -4.0% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 30 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
Nov 01
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
Aug 02Recent updates
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Nov 06US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
Nov 01Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
Oct 31AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Oct 02Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
Sep 06Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
Aug 02AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Jul 25AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
Jul 18AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
May 30Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
Apr 04Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Mar 14Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
Jan 21Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Nov 29AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 27Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Aug 02AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion
Jun 15Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Apr 14Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)
Mar 02What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?
Feb 09Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Dec 28Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?
Sep 06An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued
Aug 02AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks
Jun 13Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Jun 08Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 589 | -21 | 27 | 45 | 8 |
| 12/31/2025 | 523 | -31 | 11 | 27 | 9 |
| 12/31/2024 | 461 | -41 | -1 | 13 | 9 |
| 9/30/2024 | 448 | -39 | -1 | 10 | N/A |
| 6/30/2024 | 430 | -40 | -20 | -8 | N/A |
| 3/31/2024 | 415 | -37 | -55 | -12 | N/A |
| 12/31/2023 | 399 | -30 | -38 | 4 | N/A |
| 9/30/2023 | 381 | -25 | -43 | 1 | N/A |
| 6/30/2023 | 366 | -28 | -48 | -3 | N/A |
| 3/31/2023 | 349 | -38 | -18 | -2 | N/A |
| 12/31/2022 | 330 | -46 | -39 | -22 | N/A |
| 9/30/2022 | 316 | -56 | -37 | -22 | N/A |
| 6/30/2022 | 303 | 53 | -32 | -20 | N/A |
| 3/31/2022 | 290 | 52 | -41 | -29 | N/A |
| 12/31/2021 | 274 | 50 | -24 | -14 | N/A |
| 9/30/2021 | 259 | 45 | -18 | -10 | N/A |
| 6/30/2021 | 243 | -57 | -14 | -6 | N/A |
| 3/31/2021 | 213 | -49 | -18 | -13 | N/A |
| 12/31/2020 | 207 | -48 | -25 | -20 | N/A |
| 9/30/2020 | 210 | -46 | -36 | -27 | N/A |
| 6/30/2020 | 212 | -50 | -44 | -34 | N/A |
| 3/31/2020 | 230 | -46 | -31 | -18 | N/A |
| 12/31/2019 | 231 | -35 | -28 | -16 | N/A |
| 9/30/2019 | 222 | -23 | -20 | -11 | N/A |
| 6/30/2019 | 216 | -20 | -11 | -3 | N/A |
| 3/31/2019 | 209 | -17 | -14 | -8 | N/A |
| 12/31/2018 | 202 | -21 | -10 | -4 | N/A |
| 9/30/2018 | 195 | -20 | -10 | -4 | N/A |
| 6/30/2018 | 187 | -20 | N/A | -9 | N/A |
| 3/31/2018 | 180 | -27 | N/A | -9 | N/A |
| 12/31/2017 | 175 | -27 | N/A | -9 | N/A |
| 9/30/2017 | 170 | -33 | N/A | -10 | N/A |
| 6/30/2017 | 166 | -32 | N/A | -9 | N/A |
| 3/31/2017 | 160 | -34 | N/A | -14 | N/A |
| 12/31/2016 | 155 | -33 | N/A | -15 | N/A |
| 9/30/2016 | 150 | -36 | N/A | -20 | N/A |
| 6/30/2016 | 143 | -35 | N/A | -18 | N/A |
| 3/31/2016 | 135 | -32 | N/A | -10 | N/A |
| 12/31/2015 | 129 | -27 | N/A | -8 | N/A |
| 9/30/2015 | 123 | -22 | N/A | -6 | N/A |
| 6/30/2015 | 118 | -16 | N/A | -10 | N/A |
| 3/31/2015 | 112 | -14 | N/A | -16 | N/A |
| 12/31/2014 | 107 | -16 | N/A | -22 | N/A |
| 9/30/2014 | 99 | -16 | N/A | -23 | N/A |
| 6/30/2014 | 93 | -18 | N/A | -21 | N/A |
| 3/31/2014 | 87 | -17 | N/A | -17 | N/A |
| 12/31/2013 | 81 | -11 | N/A | -5 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ATRC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ATRC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ATRC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ATRCDie Einnahmen des Unternehmens (12.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: ATRCDie Einnahmen des Unternehmens (12.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ATRC wird voraussichtlich in 3 Jahren unrentabel sein.